Drug
Kpl 387
Kpl 387: highest development phase Phase 2/3, developed by Kiniksa Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Kiniksa Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| KPL-387 NCT07010159 | Phase 2/3 | Pericarditis |
| KPL-387 NCT07288216 | Phase 2 | Recurrent Pericarditis |
Latest
No recent events.
Follow Kpl 387 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.